Werewolf Therapeutics Files 8-K

TL;DR

Werewolf Therapeutics (HOWL) filed a standard 8-K updating corporate info.

AI Summary

Werewolf Therapeutics, Inc. filed an 8-K on June 1, 2024, to report its current status. The filing confirms the company's principal executive offices are located at 200 Talcott Ave, 2nd Floor, Watertown, Massachusetts, 02472, and its telephone number is (617) 952-0555. The company's common stock trades on The Nasdaq Global Select Market under the symbol HOWL.

Why It Matters

This 8-K filing serves as a routine update on the company's basic corporate information and stock exchange listing.

Risk Assessment

Risk Level: low — This filing is a routine corporate update and does not contain material non-public information that would typically affect stock price.

Key Players & Entities

• Werewolf Therapeutics, Inc. (company) — Registrant
• June 1, 2024 (date) — Date of earliest event reported
• 200 Talcott Ave, 2nd Floor, Watertown, Massachusetts, 02472 (location) — Principal Executive Offices
• (617) 952-0555 (phone_number) — Registrant's telephone number
• HOWL (ticker) — Trading Symbol for Common Stock
• The Nasdaq Global Select Market (exchange) — Exchange where Common Stock is registered

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share HOWL The Nasdaq

Filing Documents

• d800910d8k.htm (8-K) — 40KB
• d800910dex991.htm (EX-99.1) — 22KB
• d800910dex992.htm (EX-99.2) — 33KB
• g800910ex99_2p10g1.jpg (GRAPHIC) — 320KB
• g800910ex99_2p11g1.jpg (GRAPHIC) — 340KB
• g800910ex99_2p12g1.jpg (GRAPHIC) — 205KB
• g800910ex99_2p13g1.jpg (GRAPHIC) — 216KB
• g800910ex99_2p14g1.jpg (GRAPHIC) — 440KB
• g800910ex99_2p15g1.jpg (GRAPHIC) — 455KB
• g800910ex99_2p16g1.jpg (GRAPHIC) — 435KB
• g800910ex99_2p17g1.jpg (GRAPHIC) — 397KB
• g800910ex99_2p18g1.jpg (GRAPHIC) — 354KB
• g800910ex99_2p19g1.jpg (GRAPHIC) — 503KB
• g800910ex99_2p1g1.jpg (GRAPHIC) — 559KB
• g800910ex99_2p20g1.jpg (GRAPHIC) — 395KB
• g800910ex99_2p21g1.jpg (GRAPHIC) — 277KB
• g800910ex99_2p22g1.jpg (GRAPHIC) — 417KB
• g800910ex99_2p23g1.jpg (GRAPHIC) — 333KB
• g800910ex99_2p24g1.jpg (GRAPHIC) — 248KB
• g800910ex99_2p2g1.jpg (GRAPHIC) — 464KB
• g800910ex99_2p3g1.jpg (GRAPHIC) — 114KB
• g800910ex99_2p4g1.jpg (GRAPHIC) — 302KB
• g800910ex99_2p5g1.jpg (GRAPHIC) — 302KB
• g800910ex99_2p6g1.jpg (GRAPHIC) — 282KB
• g800910ex99_2p7g1.jpg (GRAPHIC) — 369KB
• g800910ex99_2p8g1.jpg (GRAPHIC) — 275KB
• g800910ex99_2p9g1.jpg (GRAPHIC) — 415KB
• g800910g0601082010255.jpg (GRAPHIC) — 3KB
• 0001193125-24-152380.txt ( ) — 11844KB
• howl-20240601.xsd (EX-101.SCH) — 3KB
• howl-20240601_lab.xml (EX-101.LAB) — 18KB
• howl-20240601_pre.xml (EX-101.PRE) — 11KB
• d800910d8k_htm.xml (XML) — 4KB

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated June 1, 2024. 99.2 Investor Presentation, dated June 3, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) Cautionary Note Regarding Forward-Looking Statements Any statements in this Current Report on Form 8-K about the Company's future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to substantial risks and uncertainties and actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include statements regarding the Company's strategy, future operations, prospects, plans, objectives of management, the expected timeline regarding the clinical development of product candidates, including the announcement of data, the potential activity and efficacy of product candidates in preclinical studies and clinical trials, and the timing and outcome of planned meetings with regulatory authorities. The words "aim," "anticipate," "approach," "believe," "contemplate," "continue," "could," "design," "designed to," "engineered," "estimate," "expect," "goal," "intend," "may," "might," "objective," "ongoing," "plan," "potential," "predict," "project," "promise," "should," "target," "will," or "would," or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intention

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. WEREWOLF THERAPEUTICS, INC. By: Date: June 3, 2024 /s/ Timothy W. Trost Timothy W. Trost Chief Financial Officer and Treasurer

View Full Filing

View this 8-K filing on SEC EDGAR